<DOC>
	<DOCNO>NCT01262924</DOCNO>
	<brief_summary>The purpose study assess immunogenicity reactogenicity GlaxoSmithKline ( GSK ) Biologicals ' ( formerly , SmithKline Beecham Biologicals ) reduced-antigen-content acellular pertussis vaccine reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine comparison Tedivax-Adult™/ Td-Rix™</brief_summary>
	<brief_title>Study Reduced-antigen-content Acellular Pertussis Vaccine Diphtheria-Tetanus-Acellular Pertussis Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female age ≥18 year time vaccination Free obvious health problem establish medical history clinical examination enter study Written inform consent obtain subject If subject female , must nonchildbearing potential , i.e. , either surgically sterilise one year postmenopausal ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . For annex phase study , subject must meet inclusion criterion mention . In addition , subject must receive either reducedantigencontent diphtheriatetanus diphtheriatetanusacellular pertussis vaccine initial phase study respond either diphtheria tetanus toxoid.. Vaccination diphtheria and/or tetanus within previous five year Vaccination pertussis since childhood History diphtheria and/or tetanus Known history pertussis within previous five year Known exposure diphtheria pertussis within previous five year Known history nonresponse diphtheria , tetanus pertussis vaccine Use investigational nonregistered drug vaccine study vaccine ( ) study period within 30 days/ 5 halflives precede dose study vaccine Administration chronic immunosuppressant immunemodifying drug within six months/ 5 halflives vaccination . Planned administration/ administration vaccine foreseen study protocol period start 30 day vaccination end 30 day Administration immunoglobulins and/or blood product within three month precede vaccination plan administration/ administration study period Any confirm suspected immunosuppressive immunodeficient condition Pregnant lactate female History allergic disease reaction likely exacerbate component vaccine Hypersensitivity component vaccine Acute disease time enrolment Oral temperature ≥37.5°C ( 99.5°F ) Any follow occur previous administration diphtheriatetanuspertussis vaccine diptheria tetanus vaccine An immediate anaphylactic reaction Signs encephalopathy Any follow occur previous administration diphtheriatetanuspertussis vaccine alone combination antigen : Rectal temperature ≥40.5°C within 48 hour vaccination due another identifiable cause Collapse shocklike state within 48 hour vaccination Persistent , inconsolable scream cry last ≥3 hour within 48 hour vaccination Convulsions without fever , occur within 3 day vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Booster vaccination</keyword>
</DOC>